Work

Bioprocess Development of a Human Monoclonal Antibody against MERS-CoV: Analytical and Preclinical Studies

Year: 2026

Type: article

Abstract: . To ensure stability and facilitate rapid deployment in outbreak scenarios, a lyophilized formulation of KNIH-88 was developed, maintaining structural integrity and biological activity under long-term storage. Collectively, these findings support KNIH-88 as a promising therapeutic antibody for MERS-CoV, combining potent antiviral efficacy, structural stability, and a formulation suitable for stockpiling and emergency use in endemic regions.

Source: Biomolecules & Therapeutics

DOI: 10.4062/biomolther.2026.001